Report / Paper metadata
70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.
A biomedical paper record. This page preserves its title, publication metadata and identifier, not the full article. The title alone does not establish the study findings or their clinical importance.
Limits
No clinical review has been performed. This record is not a treatment recommendation, eligibility confirmation or current availability guarantee.
- Kind
- Paper metadata